Skip to main content

Spinal and Bulbar Muscular Atrophy

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
BVS857Phase 2
Nido Biosciences
Nido BiosciencesMA - Boston
1 program
1
NIDO-361Phase 21 trial
Active Trials
NCT06411912Completed54Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
Nido BiosciencesNIDO-361

Clinical Trials (1)

Total enrollment: 54 patients across 1 trials

A Study of NIDO-361 in Patients With SBMA

Start: Mar 2024Est. completion: Oct 202554 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.